Stocks to Watch: Intel, PTC Therapeutics, KLA
By Sabela Ojea
Intel on Thursday delivered a muted outlook for sales in its current quarter. Shares of the chipmaker dropped 10%, to $44.52, in after-hours trading.
The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on PTC Therapeutics' Translarna authorization following a re-examination procedure. Shares of the biopharmaceutical company declined 12%, to $23.50, in after-hours trading.
KLA posted a profit miss in its fiscal second quarter amid weaker demand for its products. Shares of the maker of equipment for the semiconductor industry fell 5.9%, to $603.75, in after-hours trading.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
January 25, 2024 18:44 ET (23:44 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now